Femasys Inc (FEMY)

$0.52 +0.01 (1.43%)
Market Cap 31.30M
Revenue (ttm) 1.63M
Net Income (ttm) -18.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,154.60%
Debt to Equity Ratio 0.02
Volume 883,600
Avg Vol 1,444,132
Day's Range N/A - N/A
Shares Out 58.48M
Stochastic %K 11%
Beta -2.54
Analysts Strong Sell
Price Target $4.50

Company Profile

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-genera...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 770 500 3910
Fax: 404 581 5903
Address:
3950 Johns Creek Court, Suite 100, Suwanee, United States
goldenxb
goldenxb Feb. 3 at 10:18 PM
$FEMY what’s going on AH?
1 · Reply
fernqam
fernqam Feb. 3 at 7:07 PM
$FEMY Hopefully we get a massive order!!!!
1 · Reply
Ked1977
Ked1977 Feb. 3 at 6:28 PM
$FEMY so not only do we not stay up on good news we go down more. This firm needs better PR!
0 · Reply
TripTrap
TripTrap Feb. 3 at 6:17 PM
$FEMY Time for Mirto to enter the stage to our left - perfect time for him to give us his upbeat comments! No doubt, disappointing price action. Obviously we’re just not ready to go up yet.
0 · Reply
Severian1
Severian1 Feb. 3 at 6:16 PM
$FEMY Remember the only news that matters to Femy is beating revenue or buyout. dont expect jumps from prs like this
0 · Reply
steve04240
steve04240 Feb. 3 at 5:32 PM
$FEMY here's where that patience comes into play again and constantly Progress, waiting for results
0 · Reply
TwizzlersForSale
TwizzlersForSale Feb. 3 at 5:31 PM
$FEMY
0 · Reply
Ked1977
Ked1977 Feb. 3 at 5:21 PM
$FEMY the announcement is finally something positive however the price increase was only temporary because we need to see sales and profit before the stock can really go back up.
0 · Reply
TripTrap
TripTrap Feb. 3 at 5:03 PM
$FEMY Traders are trying to fill the gap… Will they close it or will the bulls fend them off?
1 · Reply
David_M_
David_M_ Feb. 3 at 4:49 PM
$FEMY
0 · Reply
Latest News on FEMY
Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care

Jan 13, 2026, 9:00 AM EST - 21 days ago

Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care

Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device

Dec 18, 2025, 9:15 AM EST - 6 weeks ago

Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

Nov 25, 2025, 9:15 AM EST - 2 months ago

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

PMCB

Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million

Nov 3, 2025, 8:30 AM EST - 3 months ago

Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million

Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo

Oct 16, 2025, 9:00 AM EDT - 3 months ago

Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo

Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

Sep 11, 2025, 9:00 AM EDT - 5 months ago

Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand

Sep 8, 2025, 9:00 AM EDT - 5 months ago

Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand

Femasys Announces Pricing of $8.0 Million Underwritten Public Offering

Aug 25, 2025, 11:44 PM EDT - 5 months ago

Femasys Announces Pricing of $8.0 Million Underwritten Public Offering

Femasys Announces Second Quarter Financial Results for 2025

Aug 8, 2025, 4:05 PM EDT - 6 months ago

Femasys Announces Second Quarter Financial Results for 2025

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion

Aug 6, 2025, 9:00 AM EDT - 6 months ago

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

Jul 1, 2025, 9:00 AM EDT - 7 months ago

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

Jun 25, 2025, 9:00 AM EDT - 7 months ago

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

Jun 17, 2025, 9:00 AM EDT - 8 months ago

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

Jun 11, 2025, 9:00 AM EDT - 8 months ago

Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

May 29, 2025, 4:23 PM EDT - 8 months ago

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

May 8, 2025, 5:01 PM EDT - 9 months ago

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

Mar 27, 2025, 9:00 AM EDT - 11 months ago

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

Mar 19, 2025, 9:20 AM EDT - 11 months ago

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

Mar 18, 2025, 9:00 AM EDT - 11 months ago

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach

Mar 13, 2025, 8:30 AM EDT - 11 months ago

Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

Feb 25, 2025, 9:20 AM EST - 1 year ago

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

Feb 11, 2025, 9:00 AM EST - 1 year ago

Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control

Jan 30, 2025, 8:30 AM EST - 1 year ago

Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

Jan 16, 2025, 8:30 AM EST - 1 year ago

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment

Nov 26, 2024, 8:30 AM EST - 1 year ago

Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Nov 12, 2024, 8:30 AM EST - 1 year ago

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments

Oct 2, 2024, 8:30 AM EDT - 1 year ago

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments

Femasys Announces Infertility Clinic Customers from Coast to Coast

Sep 18, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Infertility Clinic Customers from Coast to Coast

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

Sep 11, 2024, 8:30 AM EDT - 1 year ago

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

Sep 9, 2024, 8:30 AM EDT - 1 year ago

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting

Sep 5, 2024, 8:30 AM EDT - 1 year ago

Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

Aug 29, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

Aug 27, 2024, 8:30 AM EDT - 1 year ago

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

Jun 27, 2024, 8:30 AM EDT - 1 year ago

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

May 17, 2024, 8:30 AM EDT - 1 year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council

May 16, 2024, 8:30 AM EDT - 1 year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

May 9, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

May 7, 2024, 8:30 AM EDT - 1 year ago

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives

Apr 18, 2024, 8:30 AM EDT - 1 year ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

Mar 28, 2024, 4:05 PM EDT - 2 years ago

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

Mar 21, 2024, 9:00 AM EDT - 2 years ago

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

Mar 20, 2024, 8:15 AM EDT - 2 years ago

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

Mar 6, 2024, 9:00 AM EST - 2 years ago

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

Feb 28, 2024, 9:00 AM EST - 2 years ago

Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

Feb 6, 2024, 8:30 AM EST - 2 years ago

Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women

Jan 26, 2024, 8:00 AM EST - 2 years ago

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women

goldenxb
goldenxb Feb. 3 at 10:18 PM
$FEMY what’s going on AH?
1 · Reply
fernqam
fernqam Feb. 3 at 7:07 PM
$FEMY Hopefully we get a massive order!!!!
1 · Reply
Ked1977
Ked1977 Feb. 3 at 6:28 PM
$FEMY so not only do we not stay up on good news we go down more. This firm needs better PR!
0 · Reply
TripTrap
TripTrap Feb. 3 at 6:17 PM
$FEMY Time for Mirto to enter the stage to our left - perfect time for him to give us his upbeat comments! No doubt, disappointing price action. Obviously we’re just not ready to go up yet.
0 · Reply
Severian1
Severian1 Feb. 3 at 6:16 PM
$FEMY Remember the only news that matters to Femy is beating revenue or buyout. dont expect jumps from prs like this
0 · Reply
steve04240
steve04240 Feb. 3 at 5:32 PM
$FEMY here's where that patience comes into play again and constantly Progress, waiting for results
0 · Reply
TwizzlersForSale
TwizzlersForSale Feb. 3 at 5:31 PM
$FEMY
0 · Reply
Ked1977
Ked1977 Feb. 3 at 5:21 PM
$FEMY the announcement is finally something positive however the price increase was only temporary because we need to see sales and profit before the stock can really go back up.
0 · Reply
TripTrap
TripTrap Feb. 3 at 5:03 PM
$FEMY Traders are trying to fill the gap… Will they close it or will the bulls fend them off?
1 · Reply
David_M_
David_M_ Feb. 3 at 4:49 PM
$FEMY
0 · Reply
frchmn
frchmn Feb. 3 at 3:45 PM
$FEMY some hope!
0 · Reply
TripTrap
TripTrap Feb. 3 at 3:26 PM
$FEMY I think there is a good chance this is the bottom. We have significant volume coming in and we gapped up on the open. Almost all major trend changes start or have a gap near their beginnings (breakaway gap). The gap today is between yesterday's close .5160 and today's current low at .5338. There are other reasons I feel this way as well but the bottom line is - if they can keep this mornings gap open then we have found a significant bottom. Let's see how this plays out...
0 · Reply
steve04240
steve04240 Feb. 3 at 3:26 PM
$FEMY slow and steady...atta girl!
0 · Reply
Bluesir
Bluesir Feb. 3 at 3:17 PM
$FEMY Great news! Nice to have Switzerland on board, it could help much in finding other European Partners. 👍
0 · Reply
JS10gamer007
JS10gamer007 Feb. 3 at 2:58 PM
$FEMY we are going up and building more confidence we need to break vwap and we will rocket
0 · Reply
steve04240
steve04240 Feb. 3 at 2:57 PM
$FEMY wonder what the holdup is in the United States
1 · Reply
wolfden2000
wolfden2000 Feb. 3 at 2:42 PM
$FEMY today’s press release is very good -Switzerland has a population of about 9 mil. Women 25-60 4.5 million. Nice target audience.
1 · Reply
steve04240
steve04240 Feb. 3 at 2:26 PM
$FEMY
0 · Reply
TripTrap
TripTrap Feb. 3 at 2:26 PM
$FEMY --NEWS OUT-- February 03, 2026 09:15 ET Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products-- Multi-Product Distribution Agreement Marks Continued Commercial Momentum in Europe --| Source: Femasys Inc. https://www.globenewswire.com/news-release/2026/02/03/3231201/0/en/Femasys-Expands-European-Commercial-Footprint-with-Swiss-Partner-for-FemBloc-FemaSeed-and-Portfolio-Products.html
0 · Reply
DARKP00L
DARKP00L Feb. 3 at 2:22 PM
$FEMY 09:16 on Feb. 03 2026 Femasys Partners With OR Consulting Over Commercial Rollout Of Product Portfolio In Switzerland #tradeideas
0 · Reply
steve04240
steve04240 Feb. 3 at 12:55 PM
$FEMY sent an email asking about shareholder value.. typical response I suppose
3 · Reply
4RiskyBusiness4
4RiskyBusiness4 Feb. 2 at 6:56 PM
$FEMY Key psychological level. Watching closely. Would absolutely add heavy south of here, were that to happen. Likely triple the position.
0 · Reply